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Inferior outcome of two-haplotype matched (2-HM) renal transplants
in blacks: Role of early rejection. Acute rejection in the early post-
transplant period is a major determinant of long-term outcome. A cohort
analysis was performed to evaluate the race-specific incidence rates of
early acute rejection episodes (AR) and delayed graft function (DGF) in
Americans of African (blacks) and European (whites) descent (N = 2565)
who received a 2-HM living-related donor (LRD) first kidney transplant
between 1984 and 1992. After adjusting for center and recipient charac-
teristics, blacks had a higher incidence of AR during the initial transplant
hospitalization (blacks 13.2% vs. whites 7.4%, OR = 1.64, P = 0.02). DGF
also occurred more frequently in blacks (unadjusted OR = 1.58, P = 0.07).
Blacks with AR had significantly worse Cox-adjusted five year graft
survival than similarly affected whites (blacks 50% vs. whites 76%, P <
0.01). We conclude that failure to take immunosuppressive medications
cannot be implicated as a cause of the higher incidence of AR during the
initial transplant hospitalization in black kidney transplant recipients. The
excess risk of AR in blacks may reflect previously reported intrinsic
differences in immune responsiveness and/or pharmacokinetics of immu-
nosuppressive agents. The profound deleterious effect of AR appears to
be largely responsible for the accelerated rate of late graft loss in African
Americans.
Most studies of the outcome of kidney transplantation have
found that African American (black) renal transplant recipients
have inferior short- and long-term graft survival when compared
to recipients of other races [1—3]. This observation has been
reported in both well matched living-related donor (LRD) and
poorly-matched cadaveric donor transplants (CAD) [4—9]. By
contrast, some studies from single centers have reported similar
graft survival in black and Caucasian (white) recipients [10—14].
Several explanations for racial differences in graft survival have
been postulated including unidentified HLA antigens, immune
hyperresponsiveness, medical noncompliance, socioeconomic sta-
tus, post-transplant hypertension, and center-specific variability
[1, 15—17]. Noncompliance is frequently cited as a cause of
inferior graft survival in black recipients of well-matched living-
related transplants [3, 18].
The purpose of the present study was to determine the early
principal determinant(s) of racial differences in graft survival in
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two-haplotype matched (2-HM) LRD transplant recipients. Use
of this population eliminates differences in immune responses
resulting from HLA antigen mismatch and unmeasured genetic
differences which could confound similar analyses of cadaveric
transplantation. In addition, limiting the study to LRD transplan-
tation ensures that the health status and kidney function of the
donor have been carefully evaluated and that organs were har-
vested, preserved, and transplanted under optimal conditions.
Early acute rejection episodes (AR), delayed graft function
(DGF), and elevated discharge serum creatinine (Sr) levels have
been shown to be major determinants of subsequent graft survival
[19—26]. We reasoned that the occurrence of allograft dysfunction
in the immediate postoperative in-hospital period should be
independent of the potential effects of socioeconomic factors and
noncompliance. We hypothesized that: (1) AR, DGF, and Sr
>221 molIliter (>2.5 mg/dl) occur more frequently in black
recipients of 2-HM LRD transplants during the initial transplant
hospitalization; (2) the presence of these early indicators of poor
graft survival disproportionately affect the later outcomes for
black recipients; and (3) these findings (1 and 2) are more likely
to reflect biological differences and, because of the design of the
study, that these differences are unlikely to result from the health
of the donor, quality of the donor organ, preservation injury,
socioeconomic factors or noncompliance. The following analyses
support these hypotheses affirmatively.
Methods
Data were retrieved from the United States Renal Data System
(USRDS) database [27]. Patient-specific and transplant center
information in the USRDS were derived from the Transplant
Follow-up and the Facility Survey instruments which are period-
ically and sequentially completed as a Health Care Financing
Administration (HCFA) requirement by all transplant providers
for each transplant performed in the United States as long as the
patient lives and the transplant functions. Pretransplant end-stage
renal disease (ESRD) patient data were obtained from the
modality sequence and medical evidence modules of the USRDS
database. The study cohort was selected from all Medicare
living-related donor (LRD) renal transplants in the database. The
study cohort consisted of Americans of African ("blacks") and
European ("whites") ancestry who received a 2-HM LRD first
renal transplant between January 1984 and December 1992. The
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recipient race identification employed in this study is the self-
definition provided by the patient or surrogate in the Chronic
Renal Disease Medical Evidence Report [4]. Multiple quality
control filters and cross checks were performed on each data
element by HCFA and the USRDS. The data elements were
recorded and verified by the investigators prior to incorporation
into the analysis file. The completeness and reliability of the
database is periodically assessed and stands at 93 to 97% [28, 29].
Between 1984 and 1992, 3256 first LRD HLA-identical renal
transplants were compiled in the USRDS database. The current
study is based on 2899 transplants which met the following
criteria: (i) HLA typing at the transplant center confirmed the
donor-recipient pair as HLA-identical; (ii) one or two HLA
antigens were identified and identical at each of the HLA-A,
HLA-B and HLA-DR loci in the donor-recipient pair; and (iii)
there was no identified HLA antigen mismatch at any of the three
HLA loci. In addition, a "blank" HLA antigen at any one locus
matched to a recognized antigen at the corresponding site in
either the donor or the recipient was presumed to be a non-
matched pair and was excluded from the study. Based on these
criteria, 357 transplants (60 blacks and 297 whites) reported as
HLA-identical by the responding transplant centers were ex-
cluded from the study. The first follow-up period was from the day
of transplantation until discharge from the transplant hospitaliza-
tion. During this period, episodes of acute rejection, cyclosporine
immunosuppression, delayed graft function, and discharge serum
creatinine were recorded. A diagnosis of acute rejection was
based on clinical and/or histological criteria according to the
conventional practice of the responding transplant centers. There
was no requirement for histologic confirmation of acute rejection
in the study cohort. Delayed graft function was defined as an
initial decline in post-transplant serum creatinine by less than 265
mol/1iter (3.0 mg/dl) in addition to a need for dialysis during the
first post-transplant week. After discharge from the transplant
hospitalization, patient and allograft outcome were followed to
the earliest of either graft failure, transplant nephrectomy, death
or December 31, 1993. The use of cyclosporine during follow-up
was also recorded. The final analysis file included the following
additional variables: primary cause of ESRD, donor and recipient
age, donor and recipient gender, recipient's pretransplant health
status, duration of ESRD prior to transplantation, level of panel
reactive antibodies (PRA) at the time of transplantation, trans-
plant center indicator (see below), coverage by private health
insurance in addition to Medicare and the year of transplantation.
In order to account for the variability in the outcome of kidney
transplantation across transplant centers ("center effect") [30], we
constructed an indicator of the success rate for each center based
on the center's Kaplan-Meier one-year allograft survival of white-
donor-to-white-recipient first cadaveric renal transplants. The
one-year allograft survival at each center was averaged for trans-
plants performed between 1989 and 1991. The 238 centers
reporting 2-HM LRD transplants during the study period were
then divided into two groups, being above or below the mean
indicator variable for all centers. In addition, center effect was
estimated by transplant center size (number of LRD transplants
performed at each center during the study period) and also the
fraction of LRD transplants in black recipients at each center.
Coverage by private health insurance in addition to Medicare
was used as a surrogate of recipient's socioeconomic status. This
served as an indicator of economically-related compliant behavior
Table 1. Primary causes of ESRD among recipients of two-haplotype-




Glomerulonephritis 99 (29.6) 780 (30.4) NS
Diabetes mellitus 41(12.3) 651 (25.4) 0.001
Hypertension 90 (27) 158 (6.2) 0.001
Polycystic kidney disease and 3 (0.9) 111(4.3) 0.002
other cystic conditions
Urologic diseases 8 (2.4) 212 (8.3) 0.001
Other causes 43 (12.9) 210 (8.2) 0.004
Unknown 19 (5.7) 186 (7.3) NS
Missing 31(9.2) 258 (10.0) NS
NS indicates not significant (P value >0.10)
as has been shown in both black and white renal transplant
recipients [31].
Differences in baseline categorical characteristics and continu-
ous variables between black and white recipients were tested by
Chi-square and Student's t-test, respectively. Multivariable anal-
yses were performed with the logistic regression technique [32]
using pre-discharge acute rejection as the dependent variable.
Explanatory variables for the logistic regression model included
recipient's race, age, gender, primary cause of ESRD, transplant
year, pretransplant duration of dialysis therapy, health insurance
coverage, transplant center CAD success rate, cyclosporine use,
level of panel reactive antibodies and DGF. The adjusted odds
ratio (OR) of AR in blacks was determined with white recipients
as the reference group (OR = 1.00). Model goodness of fit was
assessed on split samples with the Hosmer and Lemeshow chi-
square statistic [32, 33].
Graft survival at one and five years post-transplant was deter-
mined by a Cox proportional hazard regression model with
adjustment for the sociodemographic and clinical characteristics
of the recipients [34]. Cox-adjusted actuarial survival curves were
constructed to determine the influence of early acute rejection on
one-year and five-year graft survival, respectively. Ninety-five
percent (95%) confidence intervals and an alpha level of 0.05 were
used for reporting statistical significance. All tests of statistical
significance were two-sided. All analyses were performed with the
Statistical Analysis Software (SAS) System Release 6.10, 1994
(SAS Institute Inc., Cary, NC, USA).
Results
Recipient characteristics
The median follow-up period for the 2899 first LRD transplants
was 54 months. Blacks constituted 11.5% of all recipients (N =
334). Table 1 shows the distribution of primary causes of ESRD in
the study population. Diabetes mellitus as a cause of ESRD was
twice as frequent among whites as among blacks (25.4% vs.
12.3%, P < 0.01), while ESRD due to essential hypertension was
present in a significantly higher proportion of black recipients
(27.0% vs. 6.2%; P < 0.01). Table 2 shows the baseline charac-
teristics of the recipients. Black donors were on average slightly
younger than white donors, whereas recipient ages at transplan-
tation were similar in both groups. Male recipients were in the
majority in both groups. According to the levels of panel reactive
antibodies at the time of transplantation, the proportion of
sensitized patients was twice as high in blacks as compared to
1594 Ojo et al: Race, early acute rejection and graft survival
Table 2. Baseline characteristics of two-haplotype-matched (2-HM)
living-related donor (LRD) renal transplant recipients: 1984—92
Characteristic
Blacks Whites
(N = 334) (N = 2565) P value
Mean donor age years 32.6 34.5 <0.005
Mean recipient age at transplant 33.8 34.5 NS
years
Male % 180 (54) 1513 (59) NS
Percentage of patients with N (%)
Onset of ESRD to transplant 147 (43.3) 552 (21.5) 0.001
>1 year
Panel reactive antibodies 19 (5.8) 77 (3.0) 0.008
(PRA) >50% at
transplantation
Cyclosporine-based 196 (58.6) 1318 (51.4) 0.014
immunosuppressive regimen
Transplants performed at 194 (58.0) 1752 (68.3) 0.001
center with "above average"
results
Transplants performed in 164 (49.1) 1452 (56.6) 0.010
1984-88
Supplemental health insurance 85 (25.5) 780 (30.4) 0.069
(Employer-paid Group
Health Plan)
NS indicates not significant (P value >0.10)
whites. On the average, black recipients were more likely to
receive cyclosporine-based immunosuppressive therapy (CsA)
than were whites (blacks 58.6% vs. whites 5 1.4%, P < 0.05). The
use of CsA in 2-HM transplants increased from 39% and 24% in
1984 to 90% and 85% in the blacks and whites, respectively (Fig.
1). Discontinuation of CsA at six monthly and yearly follow-up
was reported in 1.52% of whites and 0% of blacks. The proportion
of recipients who had received pretranspiant blood transfusion
was 57% and 60% in the black and white groups, respectively.
Nineteen percent of blacks and 18.4% of white recipients had
receive more than five units of blood prior to transplantation.
Based on the transplant center's cadaveric transplant success rate,
a significantly lower fraction of 2-HM transplants in blacks
occurred at centers with "above average" results (blacks 58.6% vs.
whites 68.3%, P < 0.01). Private health insurance coverage
(employer-paid group health plan) occurred slightly more fre-
quently in whites than in blacks (30.4% vs. 25.5%, P < 0.10). The
pretransplant functional status of recipients was similar in both
races.
Incidence and relative risks of adverse graft events during the
initial transplant hospitalization
The results of univariate analysis of early acute rejection (AR),
delayed graft function (DGF) and elevated discharge serum
creatinine are displayed in Table 3. The incidence of first acute
rejection episodes during the initial transplant hospitalization was
13.2% (44 patients) in blacks and 7.4% (189 patients) in whites,
respectively (unadjusted OR = 1.91, P < 0.01). DGF necessitating
at least one dialysis treatment within the first post-transplant week
occurred in 6% and 3.9% of blacks and whites, respectively
(unadjusted OR = 1.58, P = 0.07). The proportion of recipients
discharged with serum creatinine >221 mol/liter (2.5 mg/dl) was
10.7% in blacks and 7.4% in whites (unadjusted OR = 1.48, P =
0.06). Multivariate logistic regression analysis was performed to
elucidate the relationship between AR and patient/transplant
characteristics. After adjusting for important risk factors including
DGF, the risk of early AR was 64% higher in blacks compared to
whites (OR 1.64, P = 0.02). Additionally, DGF and center
CAD success rate were significantly associated with the probabil-
ity of developing AR during the initial transplant hospitalization
among recipients of 2-HM transplants (Table 4). The recipient
gender, level of panel reactive antibodies, insurance coverage and
primary cause of ESRD (when classified as diabetic-ESRD vs. all
others) were not significantly associated with the risk of AR.
Recipients who were not treated with cyclosporine tended to
experience AR more frequently than those whose immunosup-
pressive regimen included cyclosporine, although this difference
was not statistically significant (OR = 1.10, P> 0.50). Analysis of
time trend showed that transplants performed in 1984 were more
likely to have suffered AR compared to those performed in 1989
(OR = 2.44, P = 0.07). When the years of transplantation were
collapsed into two eras (1984 to 1988 and 1989 to 1992) corre-
sponding to previously observed epochal improvement in renal
allograft survival [4J, transplants performed in the earlier era also
tended to have a higher risk of AR (OR = 1.83) but this trend was
not statistically significant (P = 0.15). Although there was indica-
tion of an interaction between gender and presensitization, cyclo-
sporine use and era of transplantation, and race and presensiti-
zation, these interactions did not reach statistical significance.
Given that diabetics had a trend towards lower risk of AR
(though not statistically significant) and the white recipient group
had a higher incidence of diabetes (25.4% vs. 12.3%), we per-
formed a subgroup analysis to investigate the relationship be-
tween AR and race by diabetic status. Separate multivariate
logistic regression analysis showed that black diabetic recipients
had a substantial excess risk of AR (OR = 3.23, P = 0.01)
compared to diabetic whites. Among nondiabetic recipients, the
risk of early AR in blacks was also higher than in whites (OR
1.59, P = 0.03). Thus, the higher risk of AR in blacks is statistically
significant in both diabetic and nondiabetic groups.
The center CAD success rate was a significant predictor of early
acute rejection. When the success rate in first white-to-white
cadaveric transplantation was used as an indicator of center effect
in the logistic regression model, 2-HM LRD transplants per-
formed at "below average" centers had an excess risk of acute
rejection (OR = 1.47, P < 0.01). This center-dependent variability
in the risk of early AR could not be accounted for by differences
in the use of cyclosporine since this was controlled for in the
regression model. Because of the possibility of a different center
effect in LRD versus cadaveric transplants, we employed two
additional center indicators to identify center-dependent variabil-
ity: center size (number of LRD transplants over the study period)
and percentage of LRD transplants in black recipients. These two
indicators were not predictive of the risk of early acute rejection.
Relationship between early acute rejection, cyclosporine and
long-term graft outcome
The association between AR and graft survival (GS) was
evaluated by using Cox-regression models. Figure 2 shows ad-
justed five-year GS curves for each race group with and without
AR. After adjusting for cyclosporine use and other risk factors,
the one-year GS was 95% in both blacks and whites who did not
suffer AR. As noted in previous studies, including those by the
UNOS Scientific Registry, early rejection was a significant risk
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Fig. 1. Trends of cyclosporine use in 2-HM LRD
transplantation: 1984 —1992. Symbols are:
(—S—) blacks; (---A---) whites.
Table 3. Incidence of adverse allograft events during the initial
transplant hospitalization in two-haplotype-matched living-related donor
renal transplantation (univariate analysis)
Event




Acute rejection (AR) 44 (13.2) 189 (7.4) 1.91 0.001
Delayed graft function 20 (6.0) 99 (3.9) 1.58 0.065
(DGF)
Discharge SCra > 221 31(10.7) 169 (7.4) 1.48 0.055
tmol/liter
factor for subsequent graft survival [18j. In the current study, AR
was associated with a significantly lower one-year GS in blacks
(81% vs. 95%, P < 0.01) and in whites (87% vs. 95%, P < 0.01).
However, blacks with AR had a significantly lower one-year GS
than similarly affected whites (81% blacks vs. 87% whites, P <
0.05). There were racial differences in five-year GS independent
of AR. In contrast to the one-year GS, the five-year GS was
significantly lower in blacks without AR compared to whites who
did not suffer AR (78% vs. 86%, P < 0.01). Among those who
experienced AR, the five-year GS was 50% in blacks and 76% in
whites (P < 0.01). The most striking difference in graft survival
was observed in the black recipients, among whom AR was
associated with a 36% reduction in five-year GS (78% vs. 50%, P
< 0.01). In contrast, whites with AR had a 12% reduction in
five-year GS compared to whites who did not suffer an early
rejection episode (Table 5). Because we were interested in
immunologic graft loss as an end-point, an additional analysis was
performed in which death with graft function was censored. In this
"sensitivity analysis", blacks and whites with and without AR had
one-year GS of 85%, 87%, 96% and 95%, respectively. The
corresponding five-year GS were 56%, 75%, 77% and 87%. These
results are generally similar to the survival analysis in which death
with functioning graft was treated as graft failure with one notable
exception, that is, there was no longer a significant racial differ-
Table 4. Logistic regression analysis of risk factors for acute rejection








Recipient race Whites 1.64 1.07—2.50 0.02
(blacks)
Delayed graft No DGF 4.60 2.80—7.56 <0.01
function (DGF)
ESRD due to Other causes of 0.85 0.59—1.21 NS
diabetes mellitus ESRD
PRA >50% at PRA s50% 1.11 0.41—3.00 NS
transplantation
Cyclosporine-based CsA (yes) 1.10 0.64—1.91 NS
immunosuppression
(CsA) No
Transplant center "Above 1.47 1.09—1.99 <0.01
effect ("Below average"
average" centers) centers
ESRD to transplant — 1.07 0.95—1.09 NS
(per year)
Year of transplant 1989 2.44 0.93—6.40 0.07
(1984)
Transplant era 1989—1992 1.83 0.81—4.15 NS
(1984—1988)
Gender (male) Female 0.98 0.73—1.31 NS

































1984 1985 1986 1987 1988 1989 1990 1991 1992
Year of transplant
a Serum creatinine >2.5 mg/dl
NS indicates not significant (P value >0.10).
ence in one-year GS among recipients who suffered early rejection
(85% blacks vs. 87% whites).
To address the issue of the importance of cyclosporine in
HLA-identical sibling transplantation, we used the Cox regression
model to calculate survival curves stratified for cyclosporine-based
immunosuppression and race. As shown in Table 5 and Figure 3,
among whites, the one-year GS was not significantly different














Ojo et al: Race, early acute rejection and graft survival
94%). The same is true for the five-year GS in whites (87% vs.
85%). In contrast, CsA was associated with a better graft survival
in blacks both at one year (97% CsA vs. 90% No CsA, P < 0.01)
and five years post-transplant (78% CsA vs. 67% No CsA, P <
0.05). Table 5 is a summary of the one-year and five-year GS data
by CsA treatment status and occurrence of AR which has been
adjusted for the other covariates listed in Table 4.
Discussion
Most single center and registry data reveal that African Amer-
icans have poorer renal allograft survival compared to white and
Asian recipients [1—5]. The present study was undertaken with the
USRDS data to determine whether there are differences in
outcome during the critical early post-transplant period. An
important advantage of the USRDS database is that it enabled us
to restrict the analysis of early graft outcome to a sufficiently large
subpopulation of recipients with 2-HM LRD transplantation, thus
reducing the importance of frequently advanced explanations for
racial differences in graft survival such as major HLA mismatch.
Recipients of 2-HM LRD kidney transplants were selected for the
current study also to minimize the role of unmeasured genetic
diversity as the cause of any observed differences in graft survival.


















Fig. 2. Cox-adjusted graft survival according to
_______________
race and acute rejection (AR) status in 2-HM
LRD transplantation: 1984 —1992. Symbols are:
'+0 't OU (A) whites; (•) blacks; (- - - -) + AR; (—) no
AR.
Fig. 3. Cox-adjusted graft survival according to
race and cyclosporine treatment status in 2-HM
LRD transplantation: 1984—1992. Symbols are:
(A) whites; (•) blacks; (- - - -) no CsA; (—)
+ CsA.
0 6 12 18 24 30 36
Months post-transplant
42 48 54 60
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Table 5. Cox adjusteda actuarial graft survival (%) by race, acute










No early acute rejection 95 95 86 78
Early acute rejection 87 81 76 50
Cyclosporine-based therapy 95 96 87 78
No cyclosporine 94 90 85 67
a Cox regression models of graft survival were stratified by race and
treatment status and adjusted for 9 other covariates including delayed
graft function.
Because the technical difficulty in HLA antigen phenotyping is
more profound in black recipients leading to a higher frequency of
indeterminate or "blank" HLA gene products [35—37], we im-
posed an additional restriction (beyond that of the reporting
centers) on the cohort by limiting the study population to
recipients who have typeable antigen(s) at each of the three HLA
loci. Despite this strict definition, the results show marked differ-
ences between blacks and whites in the incidence of early acute
rejection episodes and delayed graft function. These results were
unchanged when the analysis was restricted to patients with
known hyporesponsive, mixed lymphocyte culture (MLC) reac-
tions.
The current study shows that the incidence of AR is 64% higher
in blacks than in whites (13.2% blacks vs. 7.4% whites, OR = 1.64,
P = 0.02). In an analysis of 8048 LRD recipients in the UNOS
Scientific Registry [18] the incidence of pre-discharge rejection
episode among recipients of HLA-identical sibling transplants was
8.0% which is similar to the weighted mean of the incidence of
AR (8.06%) observed in the current study. Pre-discharge acute
rejection and delayed graft function have been shown to be the
strongest determinants of subsequent graft outcome when other
risk factors are taken into consideration [19, 23, 24, 38]. The fact
that blacks have a striking excess risk of these early adverse graft
events suggests that the inferior long-term results in blacks have
often been initiated by critical events during the initial transplant
hospitalization and ever before the intervening and additive effect
of noncompliant behavior can be implicated. More importantly,
the profound deleterious effects of AR and less so of DGF may be
the overriding determinants of racial disparity in long-term graft
survival.
The excess risk of AR in blacks cannot be explained by major
HLA mismatch, but a potential role of minor histocompatibility
complex antigenic differences cannot be excluded. However, little
is known about minor histocompatibility antigens in humans [39].
There is empirical evidence in support of intrinsic differences in
immune system function as a possible explanation for black/white
disparity in renal allograft outcome. Using pretransplant assess-
ment of immunologic reactivity (active T cells, T/T5 ratio,
spontaneous blastogenesis and mixed lymphocyte culture) Ker-
man et al classified recipients into weak and strong immune
responders [40, 41]. Ninety percent of blacks and 66% of whites
were classified as strong immune responders. A strong immune
responder status correlated with poorer graft survival [41, 42].
Suboptimal immunosuppression may also account for the in-
creased risk of AR in blacks. Poor cyclosporine bioavailability is
associated with increased incidence of acute rejection and also
with increased rates of graft loss [43, 44]. Early post-transplant
cyclosporine pharmacokinetic studies by Schroeder, Hariharan
and First [45, 46] demonstrated poor cyclosporine bioavailability
in black and diabetic recipients. They also demonstrated a rela-
tionship between poor cyclosporine bioavailability and acute and
chronic rejection episodes. Furthermore, studies by Sanders et al
[47] suggested that cyclosporine therapy is more critical to suc-
cessful organ retention in blacks than in whites. The current
adjusted analyses also showed that cyclosporine therapy was
associated with a 12% improvement in five-year GS in black
recipients of HLA-identical renal transplants, whereas the five-
year GS was similar in whites with or without cyclosporine
therapy.
In concert with previous Registry studies [4, 19, 22], the present
study shows lower graft survival in blacks independent of AR. The
dramatically worse five-year GS in black recipients of HLA-
identical renal allograft who suffered AR has not been previously
reported. The lower five-year GS in blacks with and without AR
when compared to their respective white counterparts may be due
to differences in immune responder status and/or cyclosporine
bioavailability as discussed above. Although the USRDS database
does not have the information to evaluate this potential explana-
tion, one may postulate that if black recipients are intrinsically
more immune responsive, the immunologic injury initiated by the
deadly handmaid of early rejection episode will be accelerated
with resultant diminution of functioning nephron mass and higher
rate of graft failure. In this respect, it should be noted that an
excess risk of DGF was also observed in the black recipients, and
it has been suggested that DGF may be immunologically mediated
by preformed antibodies [48]. The very small number of presen-
sitized patients did not permit evaluation of the relationship
between DGF and presensitization. More recently, Cosio et al
[49] showed striking racial differences in the effect of hypertension
on renal allograft survival, and thus post-transplant hypertension
may also be a major contributor to the inferior graft survival in
blacks.
An alternative explanation for the inferior graft survival in
blacks is noncompliance with immunosuppressive medications in
African American recipients, as suggested by some studies [50—
52]. Lower socioeconomic status (SES) and lack of adequate
health insurance to cover the cost of immunosuppresive medica-
tions (both factors believed to be more prevalent in blacks) are
mechanisms that could possibly lead to a higher frequency of
noncompliance [53]. Butkus, Meydrech and Raju [31] elegantly
demonstrated that noncompliance among transplant recipients is
more directly attributable to socioeconomic status than to race.
Even if noncompliance were more prevalent in black transplant
recipients as a function of SES, it is insufficient to explain the
dramatically worse long-term outcome in blacks with AR (com-
pared to blacks without AR) without postulating further that
blacks with AR are even more noncompliant than their unaffected
counterparts. This "dual noncompliance hypothesis" has a logical
merit since early acute rejection may be a marker for a "rocky"
post-transplant course characterized by increased hospitalization,
more medication side effects and other complications which may
predispose to noncompliance. However, the explanation of non-
compliance has not been properly tested by previous research,
since no single study linking noncompliance to higher rate of graft
loss in blacks has accounted for differences in early acute rejection
and/or delayed graft function in their design or analysis. We
believe that the omission of one of the strongest determinants of
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outcome in these studies calls into question the validity of
noncompliance as the primary or even a major contributor to the
differences in graft survival. Moreover, previous analyses of
compliance-related graft failure by univariate techniques which
fail to separate racial and socioeconomic effects are likely to lead
to an overstatement of the association among race and noncom-
pliance [50, 51]. Further, some longitudinal single center studies
have shown that equivalent renal allograft outcome was achiev-
able in black and white recipients when racial differences in the
rates of acute rejection episodes were reduced by vigorous
immunosuppression protocols [12, 54, 55].
A limitation of the current study is the lack of histologic
confirmation of acute rejection in all cases which may have
resulted in nondifferential diagnostic misclassification. However, a
random nondifferential misclassification of acute rejection epi-
sodes will typically deflate the magnitude of observed differences
towards the null [561. Another limitation is that the higher levels
of serum creatinine at discharge observed in blacks were not
standardized to body wt and may only reflect the recipient muscle
mass and the effect of functional "nephron dosing" [57, 58] rather
than suboptimal allograft function. The definition of two-haplo-
type matched transplantation when all six antigens are not iden-
tified in the donor-recipient pair raises the possibility of misclas-
sifying a true mismatch at any one HLA locus. We attempted to
minimize this potential source of error by limiting study eligibility
to donor-recipients pairs with typeable antigens at all loci (A, B,
and DR) to ensure that the matched haplotypes were truly
identical.
Aggregate data studies may not capture the important varia-
tions in the practice patterns among centers which could explain
some of the observed findings. An important confounding factor
is the immunosuppression used in various centers. The use of
cyclosporine in 2-HM LRD transplants has increased substantially
since 1984 with some difference in the overall degree of penetra-
tion of cyclosporine between the recipient groups (Fig. 1). Be-
cause of this variability, we adjusted for cyclosporine use in both
the analysis of early rejection episodes and subsequent graft
survival. Furthermore, because immunosuppression use at any
one center is sometimes dictated by institutional therapeutic
philosophy and expertise of the transplant providers, the adjust-
ment for "center effect" would have reduced the impact of this
source of variability across centers.
In conclusion, analysis of the U.S. experience with 2-HM
living-related donor renal transplantation during the transplant
hospitalization has permitted us to show important racial differ-
ences in the risks of critical graft events, particularly acute
rejection episodes. These early differences are also associated with
strikingly disparate long-term graft survival. The study design and
ecumenical treatment of confounding variables effectively elimi-
nates the importance of HLA antigen mismatches and medical
noncompliance from the mix of risk factors contributing to early
acute rejection episodes. Cyclosporine-based immunosuppression
substantially improves graft survival in black recipients of well-
matched LRD transplants. Our data raised the possibility that
previously reported differences in immune responsiveness and/or
bioavailability of essential immunosuppressives may be largely
responsible for the excess risks of early rejection episodes in
blacks and the subsequent racial differences in graft survival. This
fact has important implications for the selection and management
of immunosuppression protocols, which need not be the same for
all races. We suggest that comparative graft survival analyses,
particularly between races, should appropriately take into account
differences in early graft events which may have critical impact on
the long-term outcome of the allograft.
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